Mischa de Ridder1,2, Lara C Gerbrandy3, Theo M de Reijke3, Karel A Hinnen1, Maarten C C M Hulshof1. 1. Department of radiation oncology, Amsterdam UMC, Amsterdam, The Netherlands. 2. Department of radiation oncology, Leiden University Medical Center, Leiden, The Netherlands. 3. Department of urology, Amsterdam UMC, Amsterdam, The Netherlands.
Abstract
OBJECTIVE: This study evaluated the performance of the novel liquid fiducial marker (BioXmark®) in IGRT for bladder cancer. METHODS: 20 patients with muscle invasive bladder cancer were entered in this prospective, single center, Phase I-II study. The novel BioXmark® liquid markers were injected around the tumor using a flexible cystoscopy. Visibility and stability of the markers were evaluated on planning-CT and CBCT. Prospectively defined threshold for success was set at a visibility of 75%. RESULTS: In total, 76 markers were implanted in 20 patients. Of those, 60 (79% 95% CI ± 9%) were visible on CT scan. Due to the learning curve of the technique, the visibility improved in the last 75% of patients (86% visibility) compared to the first 25% of patients with 58% visibility. Concerning stability of the BioXmark® marker, all visible markers after CT acquisition were still detectable at the last CBCT without displacement. In 15/20 (75%) of the patients, three or more markers were visible on CT. No BioXmark® related adverse events were reported. CONCLUSION: The success rate of this novel fiducial marker was 79%, which is above the prospectively defined threshold rate. A distinct learning curve of the injection of the liquid marker was seen over the study period. The marker showed sustained visibility and positional stability during treatment phases and also appears to be safe and easy to inject. ADVANCES IN KNOWLEDGE: This novel liquid BioXmark® marker seems to be a very promising tool in daily-adaptive IGRT for bladder preserving chemoradiotherapy in muscle invasive bladder cancer.
OBJECTIVE: This study evaluated the performance of the novel liquid fiducial marker (BioXmark®) in IGRT for bladder cancer. METHODS: 20 patients with muscle invasive bladder cancer were entered in this prospective, single center, Phase I-II study. The novel BioXmark® liquid markers were injected around the tumor using a flexible cystoscopy. Visibility and stability of the markers were evaluated on planning-CT and CBCT. Prospectively defined threshold for success was set at a visibility of 75%. RESULTS: In total, 76 markers were implanted in 20 patients. Of those, 60 (79% 95% CI ± 9%) were visible on CT scan. Due to the learning curve of the technique, the visibility improved in the last 75% of patients (86% visibility) compared to the first 25% of patients with 58% visibility. Concerning stability of the BioXmark® marker, all visible markers after CT acquisition were still detectable at the last CBCT without displacement. In 15/20 (75%) of the patients, three or more markers were visible on CT. No BioXmark® related adverse events were reported. CONCLUSION: The success rate of this novel fiducial marker was 79%, which is above the prospectively defined threshold rate. A distinct learning curve of the injection of the liquid marker was seen over the study period. The marker showed sustained visibility and positional stability during treatment phases and also appears to be safe and easy to inject. ADVANCES IN KNOWLEDGE: This novel liquid BioXmark® marker seems to be a very promising tool in daily-adaptive IGRT for bladder preserving chemoradiotherapy in muscle invasive bladder cancer.
Authors: Adam S Baumgarten; Justin B Emtage; Richard B Wilder; Matthew C Biagioli; Shilpa Gupta; Philippe E Spiess Journal: Urology Date: 2014-01-04 Impact factor: 2.649
Authors: Mélanie Machiels; Francine E M Voncken; Peng Jin; Jolanda M van Dieren; Annemarieke Bartels-Rutten; Tanja Alderliesten; Berthe M P Aleman; Jeanin E van Hooft; Maarten C C M Hulshof Journal: Pract Radiat Oncol Date: 2019-07-04
Authors: Jonas Scherman Rydhög; Steen Riisgaard Mortensen; Klaus Richter Larsen; Paul Clementsen; Rasmus Irming Jølck; Mirjana Josipovic; Marianne Camille Aznar; Lena Specht; Thomas Lars Andresen; Per Munck Af Rosenschöld; Gitte Fredberg Persson Journal: Radiother Oncol Date: 2016-07-18 Impact factor: 6.280
Authors: Maarten C C M Hulshof; George van Andel; Arjen Bel; Pieter Gangel; Jeroen B van de Kamer Journal: Radiother Oncol Date: 2007-06-11 Impact factor: 6.280
Authors: Robert A Huddart; Emma Hall; Syed A Hussain; Peter Jenkins; Christine Rawlings; Jean Tremlett; Malcolm Crundwell; Fawzi A Adab; Denise Sheehan; Isabel Syndikus; Carey Hendron; Rebecca Lewis; Rachel Waters; Nicholas D James Journal: Int J Radiat Oncol Biol Phys Date: 2013-10-01 Impact factor: 7.038
Authors: Maurice M Garcia; Alexander R Gottschalk; Jonathan Brajtbord; Badrinath R Konety; Maxwell V Meng; Mack Roach; Peter R Carroll Journal: PLoS One Date: 2014-03-03 Impact factor: 3.240
Authors: Adham Hijab; Boris Tocco; Ian Hanson; Hanneke Meijer; Christina Junker Nyborg; Anders Smedegaard Bertelsen; Robert Jan Smeenk; Gillian Smith; Jeff Michalski; Brian C Baumann; Shaista Hafeez Journal: Front Oncol Date: 2021-02-25 Impact factor: 6.244
Authors: David Steybe; Philipp Poxleitner; Pit Jacob Voss; Marc Christian Metzger; Rainer Schmelzeisen; Fabian Bamberg; Suam Kim; Maximilian Frederik Russe Journal: BMC Med Imaging Date: 2021-10-27 Impact factor: 1.930